Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported Q3 CY2025 results exceeding the market’s revenue expectations , with sales up 1.4% year on year to $384 million. The company’s full-year revenue guidance of $1.5 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.27 per share was in line with analysts’ consensus estimates. Is now the time to buy LNTH? Find out in our full research report (it’s free for active Edge members). Lantheus (LNTH) Q3 CY20 ...